Neil Brewis
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
The tetravalent, bispecific properties of FS118, an anti-LAG-3/PD-L1 antibody, mediate LAG-3 shedding from CD4 + and CD8 + tumor-infiltrating lymphocytes.
Journal: Anti-cancer drugs
Published: February 17, 2025
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy.
Journal: Cancer research communications
Published: November 07, 2023
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation.
Journal: Cancer immunology research
Published: March 22, 2023
Antibodies as drugs-a Keystone Symposia report.
Journal: Annals of the New York Academy of Sciences
Published: November 16, 2022
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 06, 2022
FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 28, 2019
CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
Journal: Cancer immunology research
Published: October 15, 2019
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 11, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026